NEWS WRAP: Ribo Life enters Hong Kong biotech fast lane after strong debut
Shares of China’s leading developer of small interfering RNA therapeutics, or siRNA, jumped 42% in their Friday debut, and continued to climb on Monday By Doug Young Hong Kong…
Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
The small nucleic acid drugs developer has positioned itself as a leader in siRNA therapeutics, boasting one of the world’s largest pipelines of drugs using the technology Key Takeaways: Ribo…
Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely
The Chinese company profited handsomely from its investment in the German vaccine maker, and is most likely selling the stake to help service its parent’s large debtKey Takeaways:Fosun Pharma said…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
FAST NEWS: CanSino’s Covid mRNA Vaccine Approved for Clinical Trials in China
The latest: A new Covid-19 mRNA vaccine developed by CanSino Biologics Inc. (6185.HK) has been approved by China’s National Medical Products Administration to begin clinical trials in the country, the…
